ResMed Inc. logo
RMDResMed Inc.

Is the EV/Sales ratio high or low?

The EV/Sales ratio of 5.13x is 37% below its 5-year average of 8.14x, near the low end of its 5-year range (4.71x–13.79x).

As of Friday, June 26, 2026. 24.85% below its 12-month average of 6.83x.

RMD EV/Sales Ratio

RMD EV/Sales Ratio Chart

5.13x
-31.96% 1Y
RMD EV/Sales Ratio

RMD Average EV/Sales Ratio Chart

RMD EV/Sales Ratio

RMD Current vs Average EV/Sales Ratio Chart

RMD EV/Sales Ratio Metrics

EV/SALES RATIO

5.13x

EV/SALES RATIO AVG TTM

6.83x

EV/SALES RATIO AVG 3Y

6.82x

EV/SALES RATIO AVG 5Y

7.97x

EV/SALES RATIO AVG 10Y

7.61x

EV/SALES RATIO AVG 15Y

6.47x

EV/SALES RATIO AVG 20Y

5.80x

CURRENT VS TTM AVG

-24.85%

CURRENT VS 3Y AVG

-24.73%

CURRENT VS 5Y AVG

-35.66%

CURRENT VS 10Y AVG

-32.56%

CURRENT VS 15Y AVG

-20.74%

CURRENT VS 20Y AVG

-11.61%

RMD Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
ResMed Inc. (RMD)$28.81B5.13x6.83x6.82x7.97x
Biogen Inc. (BIIB)vs ›$29.82B3.36x2.83x3.28x3.56x
IQVIA Holdings Inc. (IQV)vs ›$31.12B2.75x2.92x3.24x3.53x
DexCom, Inc. (DXCM)vs ›$26.49B5.66x6.54x10.07x13.75x
Veeva Systems Inc. (VEEV)vs ›$25.68B7.37x12.17x13.24x15.50x
Medline Inc. (MDLN)vs ›$31.94B1.43x1.58x1.58x1.58x
Centene Corp. (CNC)vs ›$31.98B0.14x0.11x0.20x0.28x
Mettler-Toledo International Inc. (MTD)vs ›$25.13B6.70x7.33x7.49x8.15x
Zoetis Inc. (ZTS)vs ›$32.62B4.22x6.56x8.70x9.83x
Waters Corporation (WAT)vs ›$24.57B9.56x7.11x7.17x7.32x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/Sales Ratio FAQ

What is the EV/Sales ratio for ResMed Inc. (RMD)?
The EV/Sales ratio for RMD stock is 5.13x.
Is ResMed Inc.'s EV/Sales ratio high or low?
The EV/Sales ratio of 5.13x is 37% below its 5-year average of 8.14x, near the low end of its 5-year range (4.71x–13.79x).
What is the TTM average EV/Sales ratio for ResMed Inc. (RMD)?
The TTM average EV/Sales ratio for RMD stock is 6.83x.
What is the 3Y average EV/Sales ratio for ResMed Inc. (RMD)?
The 3Y average EV/Sales ratio for RMD stock is 6.82x.
What is the 5Y average EV/Sales ratio for ResMed Inc. (RMD)?
The 5Y average EV/Sales ratio for RMD stock is 7.97x.
What is the 10Y average EV/Sales ratio for ResMed Inc. (RMD)?
The 10Y average EV/Sales ratio for RMD stock is 7.61x.
What is the 15Y average EV/Sales ratio for ResMed Inc. (RMD)?
The 15Y average EV/Sales ratio for RMD stock is 6.47x.
What is the 20Y average EV/Sales ratio for ResMed Inc. (RMD)?
The 20Y average EV/Sales ratio for RMD stock is 5.80x.

RMD EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-255.13x
2026-06-245.07x
2026-06-234.93x
2026-06-224.86x
2026-06-184.86x
2026-06-174.80x
2026-06-165.00x
2026-06-154.97x
2026-06-125.02x
2026-06-114.96x
2026-06-104.99x
2026-06-095.08x
2026-06-084.98x
2026-06-055.06x
2026-06-045.01x
2026-06-034.80x
2026-06-024.71x
2026-06-014.80x
2026-05-294.91x
2026-05-285.25x
2026-05-275.32x
2026-05-265.37x
2026-05-225.38x
2026-05-215.40x
2026-05-205.42x
2026-05-195.37x
2026-05-185.27x
2026-05-155.21x
2026-05-145.23x
2026-05-135.23x
2026-05-125.26x
2026-05-115.13x
2026-05-085.34x
2026-05-075.35x
2026-05-065.42x
2026-05-055.37x
2026-05-045.41x
2026-05-015.30x
2026-04-305.53x
2026-04-295.70x
2026-04-285.84x
2026-04-275.97x
2026-04-245.91x
2026-04-235.90x
2026-04-225.97x
2026-04-215.95x
2026-04-206.08x
2026-04-176.14x
2026-04-166.04x
2026-04-156.16x
2026-04-146.21x
2026-04-136.20x
2026-04-106.16x
2026-04-096.13x
2026-04-086.21x
2026-04-076.08x
2026-04-066.05x
2026-04-026.03x
2026-04-015.99x
2026-03-316.04x
2026-03-305.92x
2026-03-275.93x
2026-03-265.98x
2026-03-256.09x
2026-03-246.14x
2026-03-236.13x
2026-03-206.08x
2026-03-196.12x
2026-03-186.13x
2026-03-176.28x
2026-03-166.20x
2026-03-136.21x
2026-03-126.25x
2026-03-116.46x
2026-03-106.65x
2026-03-096.81x
2026-03-066.81x
2026-03-056.88x
2026-03-046.98x
2026-03-036.96x
2026-03-026.93x
2026-02-276.90x
2026-02-266.93x
2026-02-256.80x
2026-02-246.78x
2026-02-237.03x
2026-02-206.98x
2026-02-196.90x
2026-02-186.98x
2026-02-176.89x
2026-02-136.80x
2026-02-126.62x
2026-02-116.99x
2026-02-107.10x
2026-02-097.44x
2026-02-067.32x
2026-02-057.20x
2026-02-047.09x
2026-02-036.77x
2026-02-026.86x
2026-01-306.96x
2026-01-296.94x
2026-01-287.11x
2026-01-277.04x
2026-01-267.04x
2026-01-236.96x
2026-01-227.04x
2026-01-217.15x
2026-01-206.98x
2026-01-167.10x
2026-01-157.19x
2026-01-147.16x
2026-01-137.02x
2026-01-127.11x
2026-01-096.96x
2026-01-086.92x
2026-01-076.84x
2026-01-066.87x
2026-01-056.76x
2026-01-026.74x
2025-12-316.63x
2025-12-306.70x
2025-12-296.69x
2025-12-266.74x
2025-12-246.73x
2025-12-236.74x
2025-12-226.80x
2025-12-196.75x
2025-12-186.68x
2025-12-176.78x
2025-12-166.82x
2025-12-156.98x
2025-12-126.95x
2025-12-116.96x
2025-12-106.93x
2025-12-096.79x
2025-12-086.89x
2025-12-057.07x
2025-12-046.93x
2025-12-036.93x
2025-12-026.91x
2025-12-016.84x
2025-11-287.05x
2025-11-267.03x
2025-11-257.05x
2025-11-246.90x
2025-11-216.91x
2025-11-206.72x
2025-11-196.75x
2025-11-186.78x
2025-11-176.74x
2025-11-146.73x
2025-11-136.95x
2025-11-126.97x
2025-11-116.96x
2025-11-106.89x
2025-11-076.93x
2025-11-066.88x
2025-11-056.76x
2025-11-046.79x
2025-11-036.86x
2025-10-316.80x
2025-10-306.95x
2025-10-297.18x
2025-10-287.26x
2025-10-277.34x
2025-10-247.34x
2025-10-237.51x
2025-10-227.54x
2025-10-217.59x
2025-10-207.69x
2025-10-177.59x
2025-10-167.64x
2025-10-157.64x
2025-10-147.65x
2025-10-137.73x
2025-10-107.70x
2025-10-097.87x
2025-10-088.00x
2025-10-078.02x
2025-10-067.97x
2025-10-037.89x
2025-10-027.83x
2025-10-017.67x
2025-09-307.75x
2025-09-297.67x
2025-09-267.65x
2025-09-257.57x
2025-09-247.76x
2025-09-237.81x
2025-09-227.77x
2025-09-197.74x
2025-09-187.74x
2025-09-177.69x
2025-09-167.72x
2025-09-157.68x
2025-09-127.65x
2025-09-117.78x
2025-09-107.66x
2025-09-097.91x
2025-09-087.92x
2025-09-057.85x
2025-09-047.75x
2025-09-037.62x
2025-09-027.67x
2025-08-297.77x
2025-08-287.80x
2025-08-277.99x
2025-08-268.08x
2025-08-258.10x
2025-08-228.32x
2025-08-218.17x
2025-08-208.19x
2025-08-198.10x
2025-08-188.11x
2025-08-158.07x
2025-08-148.07x
2025-08-138.17x
2025-08-128.02x
2025-08-118.05x
2025-08-088.04x
2025-08-077.94x
2025-08-068.20x
2025-08-058.34x
2025-08-048.53x
2025-08-018.17x
2025-07-317.95x
2025-07-308.12x
2025-07-298.12x
2025-07-288.00x
2025-07-258.05x
2025-07-248.00x
2025-07-238.00x
2025-07-227.82x
2025-07-217.64x
2025-07-187.54x
2025-07-177.50x
2025-07-167.44x
2025-07-157.37x
2025-07-147.43x
2025-07-117.44x
2025-07-107.55x
2025-07-097.49x
2025-07-087.50x
2025-07-077.50x
2025-07-037.51x
2025-07-027.48x
2025-07-017.49x
2025-06-307.55x
2025-06-277.46x
2025-06-267.49x
2025-06-257.54x
2025-06-247.48x
2025-06-237.44x
2025-06-207.42x
2025-06-187.34x
2025-06-177.31x
2025-06-167.36x
2025-06-137.29x
2025-06-127.38x

Showing the most recent 260 of 5,031 data points. The chart above shows the full history.

About ResMed Inc.

ResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency. Notable software offerings in its respiratory portfolio include AirView, for remote device monitoring and setting adjustments; myAir, a personalized application designed to support sleep apnea patients with education and troubleshooting for better engagement and adherence; and U-Sleep, a compliance tracking platform for home medical equipment providers. Complementing these are connectivity modules and Propeller solutions. Furthermore, ResMed offers a robust suite of out-of-hospital software. This includes Brightree, a business management platform for various home care service providers (e.g., HME, pharmacy, infusion, orthotics, prosthetics); MatrixCare, providing care management for senior living, skilled nursing, and hospice organizations; and HEALTHCAREfirst, which supplies electronic health records, billing, coding services, and analytics for home health and hospice agencies. ResMed distributes its offerings primarily to sleep clinics, home healthcare dealers, and hospitals via a global network of distributors and a direct sales force, serving approximately 140 countries. Founded in 1989, the company's headquarters are located in San Diego, California.

San Diego, CA
9,980 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Michael J. Farrell